Eli Lilly (LLY)
948.45
-26.51 (-2.72%)
NYSE · Last Trade: May 9th, 12:34 PM EDT
Detailed Quote
| Previous Close | 974.96 |
|---|---|
| Open | 974.07 |
| Bid | 949.80 |
| Ask | 950.60 |
| Day's Range | 947.51 - 980.00 |
| 52 Week Range | 623.78 - 1,133.95 |
| Volume | 3,559,176 |
| Market Cap | 907.27B |
| PE Ratio (TTM) | 41.33 |
| EPS (TTM) | 22.9 |
| Dividend & Yield | 6.920 (0.73%) |
| 1 Month Average Volume | 3,285,592 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
The weight loss drug market is on track to reach almost $100 billion.
Via The Motley Fool · May 9, 2026
GoodRx (GDRX) Q1 2026 Earnings Call Transcript
Via The Motley Fool · May 8, 2026
Omada Health (OMDA) Q1 2026 Earnings Transcript
Via The Motley Fool · May 8, 2026
The competition is far behind.
Via The Motley Fool · May 8, 2026
Omada Health (NASDAQ:OMDA) reported what executives described as a “milestone quarter” for the first quarter of 2026, highlighting 42% year-over-year revenue growth, expanding margins, and positive adjusted EBITDA alongside a raised full-year outlook.
On the earnings call, Co-Founder and CEO Sean D
Via MarketBeat · May 8, 2026
Eli Lilly's next obesity drug, retatrutide, is so popular it's already getting copied. Can Lilly compete with its own drug?
Via Investor's Business Daily · May 8, 2026
IPO stock Omada Health easily beat first-quarter sales expectations Thursday, and announced a deal with drug titan Eli Lilly.
Via Investor's Business Daily · May 7, 2026
Eli Lilly has a lofty valuation thanks to its strong GLP-1 growth, but don't count out these two competitors.
Via The Motley Fool · May 7, 2026
Mounjaro generated $8.66 billion in sales in the first quarter.
Via The Motley Fool · May 7, 2026
The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits.
Via MarketBeat · May 7, 2026
Most weight-loss stocks are built on future expectations. Eli Lilly is built on current earnings and expanding demand.
Via The Motley Fool · May 7, 2026
Eli Lilly plans to invest $4.5 billion in Indiana, expanding its U.S. manufacturing footprint and supporting new weight-loss treatments.
Via Benzinga · May 7, 2026
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting earnings this Friday before market open. Here’s what you need to know. A...
Via StockStory · May 6, 2026
While Eli Lilly has slightly lagged behind the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.
Via Barchart.com · May 6, 2026
Animal health company Elanco (NYSE:ELAN) announced better-than-expected revenue in Q1 CY2026, with sales up 14.9% year on year to $1.37 billion. The company ...
Via StockStory · May 6, 2026
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be announcing earnings results this Thursday before market open. Here’s what investors sho...
Via StockStory · May 5, 2026
Animal health company Zoetis (NYSE:ZTS) will be announcing earnings results this Thursday morning. Here’s what you need to know. Zoetis beat analysts’ revenu...
Via StockStory · May 5, 2026
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be announcing earnings results this Thursday after market hours. Here’s what investors sho...
Via StockStory · May 5, 2026
Medication company Viatris (NASDAQ:VTRS) will be announcing earnings results this Thursday before the bell. Here’s what investors should know. Viatris beat a...
Via StockStory · May 5, 2026
Schrödinger (SDGR) Q1 2026 Earnings Transcript
Via The Motley Fool · May 5, 2026
Eli Lilly shares rise as Omvoh shows 4-year disease clearance in ulcerative colitis, with consistent safety and strong Crohn's data.
Via Benzinga · May 5, 2026
Quality compounders are well-oiled machines. Their competitive advantages allow them to make profits consistently and reinvest them into projects that genera...
Via StockStory · May 5, 2026
Animal health company Elanco (NYSE:ELAN) will be reporting results this Wednesday before the bell. Here’s what investors should know. Elanco beat analysts’ r...
Via StockStory · May 4, 2026
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings this Wednesday before market hours. Here’s what investors should know. R...
Via StockStory · May 4, 2026
The company still has a strong lead in its core therapeutic area.
Via The Motley Fool · May 4, 2026